Year in Review: HER2+ Updates in Oncology | Supplements And Featured Publications

Fleshing Out HER2-Directed Therapies in GI Malignancies

January 11, 2021

The field of HER2-positive gastrointestinal malignancies witnessed a surge of data in 2020 regarding investigational agents, such as the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki, that could play a pivotal role in transforming treatment selection in the coming years.